Rank #1: Justin Klein, MD, JD, Partner at New Enterprise Associates
Feb 29 2016
Rank #2: Healthegy's Medtech Conference Bringing Together Pols, VCs and Executives to Discuss Sector's Future
A longtime proponent of the Medtech industry, Rep. Paulsen most recently co-authored a letter asking the Trump administration to remove medical technology products from a list of Chinese imports subject to protective tariffs.
The five-term Congressman also has fought against the Medical Device Tax.
The Medtech Conference co-chairs and advisory board also are pleased to honor Dave Amerson, CEO of NeoTract, as the recipient of this year’s Dealmaker of the Year Award.
The award recognizes Amerson's leadership of the urology start-up as it established its UroLift System as a critical treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Sales of UroLift were surging when Teleflex agreed to acquire the company, paying $725 million up front with the promise of another $375 million in milestone payments over the next two years.
In an interview, Justin Klein, general partner of NEA, and Amerson will discuss:
- The steps Neotract took to adopt a winning culture?
- What strategies helped the company secure support from payers, providers?
- How the deal with Teleflex came to be?
- What's next for Teleflex in Urology?
Join us on May 31st to explore this singular successful story and to better understand our entire Medtech sector.
May 29 2018
Rank #3: We Ask Anders Wold, Head of GE’s Clinical Care Solutions, Where GE Fits in Healthcare’s Future
Dec 15 2017
Rank #4: Go Go Go! Scott Huennekens Explains How Strong Bias to Action Defined Leadership at Volcano, Verb
Anyone who has swapped emails with Scott Huennekens has seen the Go Go Go signature at the bottom. They’re three little words, but they say so much about the special brand of enthusiasm Huennekens brings to leading companies like Digirad, Volcano, and most recently, Verb, the partnership between Google and Johnson & Johnson. In this podcast, Huennekens explains what he learned about maintaining momentum in Medtech. When is grit misplaced? When is hopping on a plane to Europe with no plan in hand a good idea? Huennekens will bring his insights to the Medtech Conference on May 29–30.
Apr 05 2019
Rank #5: HealthQuest’s Kong on teamwork, Medtech, and investing $225 million
Mar 30 2016
Rank #6: FundRx Finding the Formula to Bring LPs, VCs, Individuals to Fund Promising Medtech Start-Ups
Feb 24 2017
Rank #7: Klein Shares how NEA Plans to Put More Than $300 Million to Work in Medtech Companies
Jun 26 2017
Rank #8: Norwest’s Mittendorff Details Past Successes and Future Challenges Facing Healthcare Technology
Nov 17 2017
Rank #9: Newly Minted VC Stacy Enxing Seng Talks Medtech, Medtronic & Why She Joined Lightstone
Apr 28 2016
Rank #10: How Will Abbott & Auris Deals Impact Early Stage Start-ups?
May 03 2016
Rank #11: Stanford’s Yock Talks Medtech Costs, Biodesign’s Birthday, and How He Feels about Apple and Google
May 03 2017
Rank #12: Surgeon/Engineer Steve Charles Has Advice for Aspiring Inventors: Never Stop Learning; Dump Netflix
Jun 29 2018
Rank #13: Relievant CEO Kevin Hykes Shares the Advice that Led Him to Set a Successful Course as CEO
Jul 13 2018
Rank #14: Stanford’s Blumenkranz Delivers His State of Innovation Address. Spoiler: It Includes Lasers
Apr 13 2017
Rank #15: Merit Medical CEO Fred Lampropoulos Lays Out Aggressive Growth Strategy, Including Opportunistic M&A
Spoiler Alert: I missed a huge part of Merit Medical CEO Fred Lampropoulos’ life story when I did my research. I won’t say what it was, but you’ll hear it at the end. I’d fire my researcher if I had one, but instead I’ll just throw myself at the mercy of the Medtech Talk Podcast community. The good news, however, is that the thing that I missed – which would have removed Fred from Merit – didn’t happen, so he’s been able to build a multibillion-dollar Medtech that’s scooping up smaller players in the space. Fred’s an engaging fellow and we covered a lot of ground, including:
- What is Merit looking for in an acquisition target?
- How does Lampropoulos manage a publicly traded Medtech?
- Why doesn’t Utah have more Medtech start-ups?
- And finally, what does Lampropoulous have to say about the spate of bad press Medtech has been getting lately?
At the Medtech Conference on May 29–30 hear from CEOs who have led their companies through an IPO and learn what they must do to thrive on the public markets, in the panel – How to Build for an IPO … and Beyond.
Joe Army, President & CEO - Vapotherm
Tim Herbert, President & CEO - Inspire Medical Systems
Gerald R. Mattys, CEO - Tactile Medical
Feb 14 2019
Rank #16: Optum’s Clark Says Medtechs Need to Craft Effective Message to Win Support from Payers and Providers
Feb 05 2017
Rank #17: CEO Randall Recalls the Tale of Trans1 and Explains Why Omnilife Will Make Its Mark in Orthopedics
Apr 28 2017
Rank #18: Managing Director Kirk Nielsen Talks Origins, Medtech, and Versant Ventures’ new $400 Million Fund
Mar 17 2017
Rank #19: CEO Jim Buck Says Mardil Medical is Using Familiar Script to Rewrite the Rules on Treating FMR
In this podcast you'll hear:
- His tragic, but uplifting path to Medtech.
- Where his first stint as CEO went wrong.
- How he came to Mardil.
- How he believes Mardil will succeed where others haven't.
Mar 27 2018
Rank #20: Mark Gelfand, Howard Levin Discuss Coridea, Ardian and How They’re Innovating Medtech Innovation
Over the past decade, no other Medtech start-up has moved markets as much or as quickly as Ardian, the godfather of the renal denervation surge a decade ago. But the gold rush dried up in 2014 when Medtronic delivered disappointing clinical trial news that left many to declare “Renal Denervation is Dead.” Well, if we may borrow from Monty Python, renal denervation is not dead yet. In this two-part podcast, we talk with Mark Gelfand and Howard Levin, the principals of Coridea, who developed Ardian’s approach. We'll talk with them about their path to creating Coridea, the state of innovation, and, of course, how the Ardian “Opera” influenced them going forward.
Apr 29 2019